Meloxicam

규격

71125-38-7CAS 번호

615-253-8EC 번호

4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamideIUPAC 명칭

C14H13N3O4S2화학식

351.4 g/mol분자량

meloxicam; 71125-38-7; Mobic; Metacam; Mobicox; Movalis; Movatec; Mobec; Coxicam; Meloxivet; Melfax; UH-AC 62XX; Meloxicamum; Meloxidolor; Meloxoral; Rheumocam; Vivlodex; Melosus; RevitaCAM; Acticam; Contacera; Emdocam; Flexicam; Inflacam; Loxicom; Melovem; Meloxidyl; Recocam; DTXSID1020803; UHAC-62XX; VG2QF83CGL; 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; UH-AC-62 XX; ANJESO; CHEBI:6741; QMIIZ ODT; N-1539; DTXCID70803; miloxicam; N1539; ZELERIS COMPONENT MELOXICAM; SYMBRAVO COMPONENT MELOXICAM; ZYNRELEF COMPONENT MELOXICAM; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methylthiazolyl)-, 1,1-dioxide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide; Masflex; Movicox; Alloxate; Ostilox; Meloxicam Injection; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1$l^(6),2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1$l^{6},2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1$l^(6),2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1$l^{6},2-benzothiazine-3-carboxamide; Metacam Oral Suspension; RefChem:5991; OroCAM Transmucosal Oral Spray; Meloxicam Solution for Injection; M01AC06; Metacam 5 mg/mL Solution for Injection; 2H-1,2-Benzothiazine-3-carboximidic acid, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1lambda6,2-benzothiazine-3-carboxamide; 615-253-8; Meloxicam (Mobic); Parocin; Meloxicamum [Latin]; 4-Hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide; Tenaron; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; C14H13N3O4S2; UNII-VG2QF83CGL; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide; MFCD00868752; CHEMBL599; MLS000028587; s1734; 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; NCGC00018248-04; SMR000058994; Revmoksikam; Coxflam; Melonex; CAS-71125-38-7; CCRIS 9139; Movalis;; Meloxicam CRS; Recoxa;; HSDB 7741; Melox;; Mobic;; Meloxicam [USAN:USP:INN:BAN]; QAMZOVA; XIFYRM; Meloxicam (Standard); Mobic (TN); Opera_ID_2; Spectrum_001633; MELOXICAM [INN]; MELOXICAM [JAN]; MELOXICAM [MI]; MELOXICAM [HSDB]; MELOXICAM [USAN]; Spectrum2_000941; Spectrum3_000649; Spectrum4_000787; Spectrum5_001813; MELOXICAM [VANDF]; Meloxicam impurity standard; Epitope ID:613442; MELOXICAM [MART.]; MELOXICAM [USP-RS]; MELOXICAM [WHO-DD]; SCHEMBL3576; Meloxicam (JAN/USP/INN); Lopac0_000766; SCHEMBL33369; BSPBio_002257; KBioGR_001234; KBioSS_002113; MLS001304725; MLS001306413; MLS006011422; BIDD:GT0726; SCHEMBL713100; SPECTRUM1504150; Meloxicam - Bio-X trade mark; SPBio_000902; MELOXICAM [GREEN BOOK]; GTPL7220; orb1310257; orb3139837; MELOXICAM [ORANGE BOOK]; MELOXICAM [EP MONOGRAPH]; SCHEMBL23589638; HY-B0261R; KBio2_002113; KBio2_004681; KBio2_007249; KBio3_001477; ETI-511; MELOXICAM [USP MONOGRAPH]; MSK7155; GLXC-07998; HMS1922D19; HMS2089B18; HMS2096I19; HMS2234P07; HMS2236C09; HMS3259H06; HMS3372C13; HMS3372P18; HMS3655K06; HMS3713I19; HMS3744K09; HMS3884G08; HMS5079D20; ALBB-027268; HY-B0261; Tox21_111734; Tox21_113192; Tox21_201689; Tox21_302756; BBL029076; BDBM50056998; CCG-39098; EBC-12958; HSCI1_000045; MSK7155-100A; STK620505; AKOS000279442; AKOS026749959; Tox21_111734_1; AC-1325; DB00814; FH25045; KS-1084; MELOXICAM [EMA EPAR VETERINARY]; Meloxicam 100 |Ig/mL in Acetonitrile; NC00698; SMP2_000133; Meloxicam 100 microg/mL in Acetonitrile; NCGC00018248-01; NCGC00018248-02; NCGC00018248-03; NCGC00018248-05; NCGC00018248-06; NCGC00018248-07; NCGC00018248-08; NCGC00018248-10; NCGC00018248-23; NCGC00018248-24; NCGC00018248-25; NCGC00018248-26; NCGC00018248-28; NCGC00022924-03; NCGC00022924-04; NCGC00256316-01; NCGC00259238-01; NCGC00263878-02; (3E)-3-[hydroxy-[(5-methyl-1,3-thiazol-2-yl)amino]methylidene]-2-methyl-1,1-dioxo-1lambda6,2-benzothiazin-4-one; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1|E6,2-benzothiazine-3-carboxamide; BH164661; SMR000718800; Meloxicam 1000 microg/mL in Acetonitrile; DB-055490; Meloxicam 1.0 mg/ml in Dimethyl Sulfoxide; M1959; NS00000018; SW219562-1; EN300-52507; Meloxicam Solution in Acetonitrile, 100ug/mL; C08169; D00969; F20356; M02128; AB00383033-17; AB00383033-18; AB00383033_20; AN-668/13244001; Q414028; SR-01000003132-10; F2173-0387; Z1695493323; Meloxicam Working Standard (Secondary Reference Standard); 4-hydroxy-2-methyl-N-(5-methy-2-thiazolyl)-2H-1,2-benzothiazine-3-caboxamide-1,1-dioxide; 3-{hydroxy[(5-methyl-1,3-thiazol-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1lambda6,2-benzothiazine-1,1,4-trione; 4-Hydroxy-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide; 4-Hydroxy-2-methyl-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide; 4-Hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1,2-dihydro-1lambda~6~,2-benzothiazine-3-carboxamide; 4-Hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1lambda{6},2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-N-(5-methyl-2-thiazole)-2H-1,2-benzothiazine-3 -carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide; 4-Hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide1,1-dioxide; Meloxiam동의어